⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2101505 | 0.72 | AURKA (0.56) | — | |
| SCHEMBL1422273 | 0.70 | — | — | |
| SCHEMBL2645298 | 0.70 | — | — | |
| SCHEMBL6641176 | 0.69 | — | — | |
| SCHEMBL460820 | 0.69 | — | — | |
| SCHEMBL4657736 | 0.68 | — | — | |
| SCHEMBL13470772 | 0.68 | — | — | |
| SCHEMBL222454 | 0.68 | — | — | |
| SCHEMBL610916 | 0.68 | — | — | |
| SCHEMBL7834765 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861595-A2 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | Incyte Corporation (US) | 2015-04-22 | — | — | EP | claimed |
| WO-2014007951-A2 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-01-09 | — | — | WO | claimed |
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-20180280352-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3074400-B1 | OCTAHYDRO-CYCLOBUTA [1,2-C;3,4-C']DIPYRROLE DERIVATIVES AS AUTOTAXIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| CN-107311983-A | Indoles micromolecular C MET inhibitor | 北京万全德众医药生物技术有限公司 | 2017-11-03 | — | — | CN | disclosed |
| CN-103889224-B | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC医疗公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-106687445-A | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | 维颂公司 | 2017-05-17 | — | — | CN | disclosed |
| EP-3131896-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3131897-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3074400-A1 | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL | F. Hoffmann-La Roche AG (CH) | 2016-10-05 | — | — | EP | disclosed |
| EP-1761268-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006004636-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0511879-B1 | Pyrazine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |